← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Extend Biosciences, Inc.
Newton, MA
$15,267,242
Total funding
10
Grants
Funding over time
peak $3.6M · FY2013–25$5M$3.8M$2.5M$1.3M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,467,626 · 9
FDA$1,799,616 · 1
By mechanism
R44$10,942,113 · 3
R43$2,525,513 · 6
R01$1,799,616 · 1
Investigators at Extend Biosciences, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Long-acting PTH for hypoparathyroidism$2,000,000
R44 · FY2021 · DK
Long-acting PTH for hypoparathyroidism$1,928,001
R44 · FY2018 · DK
Long-acting PTH for hypoparathyroidism$1,802,798
R44 · FY2017 · DK
Long-acting ghrelin for the treatment of cancer cachexia$1,377,076
R44 · FY2018 · CA
Long-acting PTH for hypoparathyroidism$1,000,000
R44 · FY2020 · DK
Long-acting PTH for hypoparathyroidism$999,615
R44 · FY2025 · DK
Long-acting PTH for hypoparathyroidism$999,615
R44 · FY2024 · DK
A Phase 2 Study Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults with Hypoparathyroidism (IND146180; October 14, 2022)$899,808
R01 · FY2023 · FD
A Phase 2 Study Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults with Hypoparathyroidism (IND146180; October 14, 2022)$899,808
R01 · FY2025 · FD
Long-acting ghrelin for the treatment of cancer cachexia$832,924
R44 · FY2017 · CA
Long-acting ghrelin for neuropathy$535,325
R43 · FY2019 · NS
Ultralong-acting insulin for diabetes$350,000
R43 · FY2017 · DK
Long acting PTH for hypoparathyroidism$306,738
R43 · FY2015 · DK
Long-acting ghrelin for the treatment of ARS$300,000
R43 · FY2017 · AI
Long-acting ghrelin for the treatment of ARS$300,000
R43 · FY2018 · AI
A Systemically Deliverable RNAi-based Approach for Alcoholic Liver Disease$299,648
R43 · FY2013 · AA
Long lasting ghrelin derivatives for the treatment of cancer cachexia$288,302
R43 · FY2013 · CA
A Systemically Deliverable RNAi-based Approach for Alcoholic Liver Disease$145,500
R43 · FY2014 · AA
Long-acting ghrelin for the treatment of cancer cachexia$2,084
R44 · FY2019 · CA